Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Aptamer enters partnership with Microsaic Systems
(Sharecast News) - Aptamer Group announced a partnership with Microsaic Systems on Friday, to develop a panel of Optimer binders for integration into Microsaic's water testing system. The AIM-traded firm said the collaboration aimed to enhance continuous water monitoring by enabling rapid detection of multiple waterborne pathogens.
Microsaic recently acquired the Microtox water testing system.
Previous work with Aptamer's Covid-19 Optimer binders demonstrated successful integration into that system, showing superior detection performance compared to alternative affinity ligands like Affimers.
Those trials, conducted within the UK wastewater system, confirmed the efficacy of Optimer-enabled pathogen detectors.
Under the new agreement, Aptamer said it would develop Optimer binders for several major waterborne pathogens, including E.coli, cholera, cryptosporidium, legionella, and norovirus.
The binders would be integrated into Microsaic's pathogen detectors, providing rapid and sensitive detection of multiple pathogens crucial for public health.
Aptamer said the continuous water testing solution aimed to detect pathogens in real-time, eliminating delays associated with laboratory-based testing.
The system aimed for seamless integration with nationwide water systems, facilitating early detection of potential infections and enhancing public health safety.
"We are pleased to work with Microsaic and support their development of the water testing system," said chief technical officer Dr Arron Tolley
"Applying the pathogen detector within national water systems could help prevent disease outbreaks by rapidly identifying specific hotspots."
Dr Tolley said the robust nature of Optimer binders meant that they could work within tests as diverse as lab-based diagnostics and environmental water monitoring.
"Previous work has demonstrated that Optimer binders allow highly sensitive pathogen detection in the wastewater testing system, and we are pleased to build on this with the new team at Microsaic as they advance the platform to commerciality."
At 1347 BST, shares in Aptamer Group were up 5.43% at 0.74p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.